逐步的单细胞数据识别了与头癌和瘤微环境重塑发展相关的RNA结合蛋白
Bin Yang1, Wei Sun2, Ping Peng2
1Department of Thoracic Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Cancer biomarkers : section A of Disease markers
|April 2, 2025
概括
RNA结合蛋白 (RBPs) 是头部和部状细胞癌 (HNSC) 进展的关键. 这项研究揭示了它们在HNSC阶段的不同作用,确定了潜在的预后标记物和个性化治疗的治疗点.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 基因组学就是基因组学.
背景情况:
- 头部和部状细胞癌 (HNSCC) 是一种主要的全球性癌症,死亡率高.
- RNA结合蛋白 (RBPs) 对基因表达和癌症发展至关重要.
- 在单细胞水平上对HNSCC中的RBPs的理解有限.
研究的目的:
- 通过单细胞分析,研究RBPs在HNSCC逐步进展中的作用.
- 描述RBP表达模式,预后价值和途径参与.
- 确定HNSCC的潜在治疗点和生物标志物.
主要方法:
- 分析了来自HNSCC样本的单细胞RNA测序数据,跨越四个阶段 (正常,白血病,原发性,转移性).
- 检查了2141个RBP的表达,确定了基于RBP的细胞群,并评估了与疾病阶段和进展的关联.
- 使用与结果相关的 RBPs 开发了一个预后风险模型.
主要成果:
- RBPs显示细胞类型特定的表达模式与HNSCC阶段不同.
- RBP集群与癌症进展有显著的相关性.
- 一个预后模型确定了像CELF2 (在晚期下调) 和纤维细胞RBP (CFL1,PFN1) 等RBP与更好的预后相关.
- 在癌前阶段观察到RBP调节MIF信号的异质性.
结论:
- 在HNSCC的进展中,RBPs起着至关重要的作用.
- RBPs代表潜在的治疗目标和预后标记.
- 研究结果为开发个性化HNSCC治疗策略提供了洞察力.
相关概念视频
02:39lncRNA - Long Non-coding RNAs
8.4K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
8.4K
02:55The Nucleolus
8.6K
The nucleolus is the most prominent substructure of the nucleus. When it was first discovered, it was considered to be an isolated organelle that forms fibrils and granules. In 1931, the relationship between the nucleolus and chromosomes was first described by Heitz. He observed that the appearance and size of nucleolus varies depending on the stage of the cell cycle. He also noticed constricted regions on different chromosomes clustered together at definite cell cycle stages. These regions,...
8.6K